SGAM
NBIX icon

Steinberg Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Steinberg Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.4M Buy
15,923
+412
+3% +$34.4K 0.22% 107
2018
Q4 		$1.11M Sell
15,511
-7,497
-33% -$718K 0.19% 112
2018
Q3 		$2.83M Buy
23,008
+10,538
+85% +$1.2M 0.4% 80
2018
Q2 		$1.23M Buy
+12,470
New +$1.12M 0.18% 109

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steinberg Global Asset Management's NBIX Position: Q1 2019 in Review

Steinberg Global Asset Management increased its Neurocrine Biosciences (NBIX) stake by 2.7% in Q1 2019, buying an estimated $34.4K and bringing the position to 15,923 shares worth $1.4M. The position accounts for 0.22% of the portfolio, ranked #107.

Steinberg Global Asset Management first reported a position in NBIX in Q2 2018 and has held it in 4 quarters since. The position peaked at $2.83M in Q3 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • Steinberg Global Asset Management held 15,923 shares of Neurocrine Biosciences worth $1.4M as of Q1 2019.
  • Steinberg Global Asset Management bought 412 Neurocrine Biosciences shares in Q1 2019, an estimated $34.4K.
  • Neurocrine Biosciences made up 0.22% of Steinberg Global Asset Management's portfolio in Q1 2019, its #107 holding.
  • Steinberg Global Asset Management first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 4 quarters since.
  • Steinberg Global Asset Management's Neurocrine Biosciences position peaked at $2.83M in Q3 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Steinberg Global Asset Management's 13F filing for Q1 2019, filed 15 Apr 2019.